A new medication is developed that targets and binds to the lipid A portion of LPS in Gram-negative bacterial cells. This drug shows a high degree of binding and activity against purified lipid A in an experiment carried out in test tubes. Based on this information,
A) we should fast-track this drug and get it out to physicians immediately to help prevent Gram-negative toxic/septic shock in humans.
B) we should do some animal testing with intact Gram-negative cells and the medication before we jump to any conclusions.
C) we should next proceed by repeating the experiment in test tubes using intact Gram-negative cells to see if the drug binds with the same strength.
D) we should abandon the drug entirely. Binding to lipid A won't kill the bacteria, so the drug is useless to develop further.
E) we should assume that the medication will be effective against all bacteria, including Mycoplasmas, and that it is ready for use in humans.

Question

A new medication is developed that targets and binds to the lipid A portion of LPS in Gram-negative bacterial cells. This drug shows a high degree of binding and activity against purified lipid A in an experiment carried out in test tubes. Based on this information,
A) we should fast-track this drug and get it out to physicians immediately to help prevent Gram-negative toxic/septic shock in humans.
B) we should do some animal testing with intact Gram-negative cells and the medication before we jump to any conclusions.
C) we should next proceed by repeating the experiment in test tubes using intact Gram-negative cells to see if the drug binds with the same strength.
D) we should abandon the drug entirely. Binding to lipid A won't kill the bacteria, so the drug is useless to develop further. 
E) we should assume that the medication will be effective against all bacteria, including Mycoplasmas, and that it is ready for use in humans.

Quizplus · Accepted Answer

The Answer of A new medication is developed that targets and binds to the lipid A portion of LPS in Gram-negative bacterial cells. This drug shows a high degree of binding and activity against purified lipid A in an experiment carried out in test tubes. Based on this information,
A) we should fast-track this drug and get it out to physicians immediately to help prevent Gram-negative toxic/septic shock in humans.
B) we should do some animal testing with intact Gram-negative cells and the medication before we jump to any conclusions.
C) we should next proceed by repeating the experiment in test tubes using intact Gram-negative cells to see if the drug binds with the same strength.
D) we should abandon the drug entirely. Binding to lipid A won't kill the bacteria, so the drug is useless to develop further. 
E) we should assume that the medication will be effective against all bacteria, including Mycoplasmas, and that it is ready for use in humans.

A New Medication Is Developed That Targets and Binds to the Lipid